Search Results - "Molimard M"

Antidepressants: general practitioners’ opinions and clinical practice.

Authors: Rambelomanana, S. Depont, F. Forest, K. et al.

Source: Acta Psychiatrica Scandinavica. Jun2006, Vol. 113 Issue 6, p460-467. 8p. 3 Charts, 1 Graph.

Subjects: General practitioners, Antidepressants, Psychiatric drugs, Monoamine oxidase inhibitors, Neurotransmitter uptake inhibitors, Mental depression

Prognostic impact of psychoactive substances use during hospitalization for intentional drug overdose.

Authors: Tournier, M. Molimard, M. Abouelfath, A. et al.

Source: Acta Psychiatrica Scandinavica. Aug2005, Vol. 112 Issue 2, p134-140. 7p.

Subjects: Hospital care, Narcotics, Narcotic antagonists, Drug overdose, Cardiac massage, Medical care

Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.

Authors: Molimard, M. Diquet, B. Benedetti, M. Strolin

Source: Fundamental & Clinical Pharmacology. Aug2004, Vol. 18 Issue 4, p399-411. 13p.

Accuracy of self-report and toxicological assays to detect substance misuse disorders in parasuicide patients.

Authors: Tournier, M. Molimard, M. Abouelfath, A. et al.

Source: Acta Psychiatrica Scandinavica. Dec2003, Vol. 108 Issue 6, p410-418. 9p.

Subjects: Substance abuse, Drug overdose, Self-report inventories

Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation.

Authors: Molimard M Girodet PO Pollet C et al.

Source: Drug Safety. 2008, Vol. 31 Issue 9, p769-774. 6p.

Comparaison de l'utilisation des dispositifs d'inhalation par les enfants asthmatiques en pratique de ville

Alternate Title: Assessment of handling of inhaler devices in real life: an observational study in chidren in primary care

Authors: Malot, L. Molimard, M. Abouelfatah, A. et al.

Source: Archives de Pédiatrie. Oct2007, Vol. 14 Issue 10, p1190-1195. 6p.

A Randomized, Double-Blind, Double-Dummy, Safety Crossover Trial Comparing Cumulative Doses up to 96 μg of Formoterol Delivered via an HFA-134a-Propelled pMDI vs. Same Cumulative Doses of Formoterol DPI and Placebo in Asthmatic Patients.

Authors: Molimard, M. Guenolé, E. Duvauchelle, T. et al.

Source: Respiration. May2005 Supplement 1, Vol. 72, p28-34. 7p. 5 Charts, 5 Graphs.

Does use or withdrawal of long-acting β2-adrenoceptor induce desensitisation?

Authors: Molimard, M. Moore, N. Begaud, B.

Source: Lancet. 1/3/1998, Vol. 351 Issue 9095, p66-67. 2p.

PRS2 - Long-Term Impact of Grass-Pollen (GP) Sublingual Immunotherapy Tablet (SLIT) on Allergic Rhinitis (AR) and on Allergic Asthma (AA) Onset and Progression.

Authors: Devillier, P Molimard, M Demoly, P et al.

Source: Value in Health. Oct2017, Vol. 20 Issue 9, pA639-A640. 1p.

Insuffisance surrénalienne aiguë et hypercorticisme induits par des corticoïdes inhalés

Authors: Molimard, M. Pollet, C. Abouelfath, A. et al.

Source: Revue Francaise d'Allergologie & d'Immunologie Clinique. Oct2006, Vol. 46 Issue 6, p592-592. 1p.

L’effet Nocebo : particularités et conséquences pour le clinicien.

Authors: Mouly, S. Bergmann, J.-F. Molimard, M.

Source: Revue de Médecine Interne. May2018, Vol. 39 Issue 5, p315-320. 6p.

Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients.

Authors: Howarth, P. Malling, H.-J. Molimard, M. et al.

Source: Allergy. Mar2012, Vol. 67 Issue 3, p321-327. 7p. 2 Charts, 4 Graphs.

Omalizumab decreases nonspecific airway hyperresponsiveness in vitro.

Authors: Berger, P. Scotto-Gomez, E. Molimard, M. et al.

Source: Allergy. Feb2007, Vol. 62 Issue 2, p154-161. 8p. 1 Diagram, 3 Charts, 3 Graphs.

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.

Authors: Suttle, A B Ball, H A Molimard, M et al.

Source: British Journal of Cancer. 12/9/2014, Vol. 111 Issue 12, p2383-2383. 1p.

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours.

Authors: Adenis, A Ray-Coquard, I Italiano, A et al.

Source: British Journal of Cancer. 11/12/2013, Vol. 109 Issue 10, p2574-2578. 5p.

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

Authors: Mustjoki, S Auvinen, K Kreutzman, A et al.

Source: Leukemia (08876924). Apr2013, Vol. 27 Issue 4, p914-924. 11p. 1 Chart, 6 Graphs.

Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia.

Authors: Cortes, J. E. Egorin, M. J. Guilhot, F. et al.

Source: Leukemia (08876924). Sep2009, Vol. 23 Issue 9, p1537-1544. 8p. 1 Diagram, 1 Chart.

Paradoxal effect of salbutamol in an in vitro model of bronchoprotection.

Authors: Girodet, P.O. Berger, P. Martinez, B. et al.

Source: Fundamental & Clinical Pharmacology. Apr2005, Vol. 19 Issue 2, p179-186. 8p.

From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome.

Authors: Bouchet, S Dulucq, S Pasquet, J-M et al.

Source: Leukemia (08876924). Aug2013, Vol. 27 Issue 8, p1757-1759. 3p. 2 Graphs.

PRS3 RELATIVE EFFECTIVENESS STUDY OF OMALIZUMAB: THE USE OF BEFORE-AFTER COHORT METHODOLOGY FOR COVERAGE WITH EVIDENCE DEVELOPMENT

Authors: Grimaldi-Bensouda, L. Zureik, M. Molimard, M. et al.

Source: Value in Health. pA137-A137. 1p.